Prof. Shisuo Du 杜世锁
Chief Physician, Professor
Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy and comprehensive treatment for liver cancer, lung cancer, esophageal cancer, thymoma, biliary tract, gallbladder, pancreatic malignancies, and malignant melanoma. Research focuses on combining radiation with immunotherapy.
Dr. Du has practiced radiation oncology for 22 years. Dr. Du was an Associate Professor at Thomas Jefferson University (4 years) and a Postdoctoral Fellow at the NYU Cancer Center (4 years). Dr. Du participated in the Harvard University Global Clinical Scholars Research Program (2019-2020). Research focuses on liver and lung cancer radiation, radiation-induced liver injury, and immunotherapy combined with radiation.
Professional roles
- Chair, Radiation Therapy Branch, Shanghai Medical Doctor Association
- Vice Chair, Tumor Radiation Therapy and Imaging Committee, Shanghai Nuclear Society
- Standing Committee Member, Precision Radiotherapy Technology Branch, Chinese Society of Biomedical Engineering
- Standing Committee Member, Diagnosis and Treatment Integration Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Du Shisuo). Papers usually list the name as Shisuo Du or Du S.
Selected publications
70 papers on PubMed matched by name and affiliation; 25 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Mol Immunol, 2026 (first author): Author Correction: DNA sensing and associated type 1 interferon signaling contributes to progression of radiation-induced liver injury. PubMed 42463807
- Precis Radiat Oncol, 2026 (senior author): Radiotherapy and Immunotherapy In Hepatocellular Carcinoma: Priming the Tumor Immune Microenvironment From Bench To Bedside. PubMed 42500424
- Hepatol Int, 2026 (senior author): Efficacy of radiation therapy plus targeted therapy with or without immunotherapy for lymph node metastases in hepatocellular carcinoma. PubMed 42362971
- Int J Radiat Oncol Biol Phys, 2026 (first author): Corrigendum to 'Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation' [International Journal of Radiation Oncology*Biology*Physics Volume 112, Issue 5, 1 April 2022, Pages 1243-1255]. PubMed 42409272
- Int J Radiat Oncol Biol Phys, 2026 (senior author): Stereotactic Body Radiation Therapy With Continued First-Line PD-1 Inhibitor-based Therapy as a Resistance-Overcoming Strategy in Oligoprogressive Hepatocellular Carcinoma: A Prospective Phase 2 Clinical Study. PubMed 41520893
- Int J Radiat Oncol Biol Phys, 2026 (senior author): Adjuvant Chemoradiation Therapy Versus Chemotherapy Alone After Resection of Gallbladder Carcinoma: A Real-World, Inverse Probability of Treatment Weighting-Based Cohort Study. PubMed 40967375
- Cell Commun Signal, 2026 (senior author): Deciphering the intratumor microbiota in malignant gastrointestinal tumors: multifaceted interplay and clinical implications. PubMed 41593640
- Med Dosim, 2026 (senior author): Comparison of helical tomotherapy, VMAT, and DMLC-IMRT techniques used in radiotherapy of pleural disseminated thymic tumors. PubMed 42521563
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion